Obesity 2026

Dr. Lloyd L. Tran is the Chairman and Chief Executive Officer of Biomed Industries, Inc., a biotechnology company focused on developing innovative therapies for neurodegenerative, metabolic, and cardiovascular diseases. With more than 30 years of experience in pharmaceutical research and development, he has held scientific and leadership positions at major pharmaceutical and biotechnology organizations, including Pfizer and Biomed Pharmaceutical, Inc, Dr. Tran is the architect of the Unified Theory of Neurodegenerative, Metabolic, and Cardiovascular Diseases and holds multiple international patents related to therapies for Alzheimer’s disease, obesity, stroke, and metabolic disorders. He earned his Ph.D. in Medicinal Chemistry from Victoria University of Wellington, New Zealand.